Taybeh Esra' O, Alsharedeh Rawan, Hamadneh Shereen
Department of Applied Pharmaceutical Sciences, School of Pharmacy, Isra University, Amman, JOR.
Department of Pharmaceutical Sciences, School of Pharmacy, Yarmouk University, Irbid, JOR.
Cureus. 2022 Dec 15;14(12):e32561. doi: 10.7759/cureus.32561. eCollection 2022 Dec.
This study aimed to explore perceptions and willingness to get coronavirus disease 2019 (COVID-19) booster vaccination among pregnant and lactating women in Jordan.
A cross-sectional study using a 29-item web-based questionnaire was conducted. Sociodemographic characteristics, vaccine acceptance, confidence in the booster dose of COVID-19 vaccine, perception of risk for COVID-19, and acceptance to participate in COVID-19 booster vaccine clinical trials were prospectively evaluated. Logistic regression was used to identify factors that might affect the participants' acceptance of a COVID-19 vaccine and their willingness to enroll in clinical trials of a booster dose of COVID-19 vaccine.
Among all participants (pregnant and lactating women, n = 584), 328 (56.2%) intended to receive the booster dose of the COVID-19 vaccine. Predictors of booster dose acceptance were a medical-related degree (OR 1.62, CI 1.06-2.5, p = 0.028), income (OR 0.677, CI 0.52-0.88, p = 0.004), living residency (OR 0.44, CI 0.32-0.60, p < 0.001), knowing pregnant/lactating women previously infected with infectious microbe (OR 1.539, CI 1.07-2.23, p = 0.022), commitment to immunization for children (OR 3.01, CI 1.03-8.82, p = 0.044), receiving an influenza vaccine (OR 1.46, CI 1.04-2.05, p = 0.031), and worried about infectious microbes (OR 1.32, CI 1.15-1.52, p < 0.001). Among participants, only 22.9% were willing to participate in clinical trials of the booster dose of COVID-19 vaccine. The biggest motivator for participation was the participants' desire to help find the best vaccine during pregnancy/lactation (57.5%) while the main barrier towards participation was not wanting to expose themselves and their babies to more side effects (88.0%).
This study reported reasonable acceptance of vaccination in a sample of pregnant/lactating women. Vaccination hesitancy for the booster dose was in-line with similar studies on the primary series around the globe, but the willingness to participate in clinical trials was lower than non-pregnant/non-lactating women.
本研究旨在探讨约旦孕妇和哺乳期妇女对2019冠状病毒病(COVID-19)加强疫苗接种的认知和意愿。
采用基于网络的29项问卷进行横断面研究。前瞻性评估社会人口学特征、疫苗接受度、对COVID-19疫苗加强剂量的信心、对COVID-19风险的认知以及参与COVID-19加强疫苗临床试验的接受度。采用逻辑回归分析确定可能影响参与者接受COVID-19疫苗以及参与COVID-19疫苗加强剂量临床试验意愿的因素。
在所有参与者(孕妇和哺乳期妇女,n = 584)中,328人(56.2%)打算接种COVID-19疫苗加强剂量。接受加强剂量的预测因素包括医学相关学位(OR 1.62,CI 1.06 - 2.5,p = 0.028)、收入(OR 0.677,CI 0.52 - 0.88,p = 0.004)、居住地区(OR 0.44,CI 0.32 - 0.60,p < 0.001)、认识曾感染传染性微生物的孕妇/哺乳期妇女(OR 1.539,CI 1.07 - 2.23,p = 0.022)、致力于儿童免疫接种(OR 3.01,CI 1.03 - 8.82,p = 0.044)、接种过流感疫苗(OR 1.46,CI 1.04 - 2.05,p = 0.031)以及担心传染性微生物(OR 1.32,CI 1.15 - 1.52,p < 0.001)。在参与者中,只有22.9%愿意参与COVID-19疫苗加强剂量的临床试验。参与的最大动力是参与者希望在孕期/哺乳期帮助找到最佳疫苗(57.5%),而参与的主要障碍是不想让自己和宝宝面临更多副作用(88.0%)。
本研究报告了在孕妇/哺乳期妇女样本中对疫苗接种有合理的接受度。对加强剂量疫苗接种的犹豫态度与全球关于初次接种系列的类似研究一致,但参与临床试验的意愿低于非孕妇/非哺乳期妇女。